The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY PMDA Chief Vows Stronger Support for Drug Discovery, Orphan Designations
January 21, 2026
-
ORGANIZATION OTC Industry Head Urges Caution on Extra Charges for “OTC-Like” Drugs
January 20, 2026
-
REGULATORY AMED, JPMA Poised to Embed Pharma Expertise in Drug Discovery
January 20, 2026
-
REGULATORY Japan’s Lower House Poll Set for Feb. 8 after Takaichi Calls Snap Vote
January 20, 2026
-
REGULATORY Bosulif, 4 Other Drugs Escape April Re-Pricing as “Spillover” Scrapped; Lixiana, Entresto Brace for Cuts
January 19, 2026
-
REGULATORY Expert Calls for Full Verification of CEA Guidelines and Analytical Frameworks
January 16, 2026
-
REGULATORY Japan Sets New Pricing Rules for Conditionally Approved Regenerative Medicines, Starting with Elevidys
January 15, 2026
-
BUSINESS Rohto to Roll Out 3- or 4-Day Workweek Option from April to Spur Growth, Retention
January 15, 2026
-
ORGANIZATION Pharma FTC Clarifies “Simple Beverages” under New Food Rules
January 14, 2026
-
REGULATORY Japan Panel to Review AbbVie’s Aquipta, Ipsen’s Sohonos on January 23
January 13, 2026
-
REGULATORY MHLW Pharma Director Says Uniform Drug Price Hike “Not Realistic,” Targeted Support Preferred
January 9, 2026
-
BUSINESS Bayer/Santen to Launch Eylea Bio-AG on February 2
January 9, 2026
-
BUSINESS Pharma Leaders Press for Drug Pricing Overhaul at New Year’s Confab
January 8, 2026
-
BUSINESS Generic Entry into DPP-4 Class Poised to Accelerate in 2026
January 7, 2026
-
COMMENTARY Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026
January 6, 2026
-
ORGANIZATION FY2026 Reform Tilted toward Price Cuts despite Spillover Scrap: FPMAJ Chair
January 6, 2026
-
ORGANIZATION Pfizer Japan President Igarashi Takes Helm as PhRMA Japan Chair
January 6, 2026
-
ORGANIZATION Industry Leaders Call for Proper Rewards for Innovation in New Year Messages
January 5, 2026
-
REGULATORY Gist of FY2026 Drug Pricing Reform Outline
December 26, 2025
-
REGULATORY Japan Puts CEA Expansion on Hold, Sets 6-Month “Technical Discussions”
December 26, 2025
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…